AIM:To evaluate clinical efficacy of four one-week triple therapies in eradicating Helicobacter pylori infection.METHODS: In this clinical trial, 132 patients with duodenal ulcer and chronic gastritis were randomly di...AIM:To evaluate clinical efficacy of four one-week triple therapies in eradicating Helicobacter pylori infection.METHODS: In this clinical trial, 132 patients with duodenal ulcer and chronic gastritis were randomly divided into four groups, and received treatment with OAC (omeprazole 20mg+amoxicillin 1000mg+clarithromycin 250mg), OFC (omeprazole 20mg+furazolidone 100mg+clarithromycin 250mg), OFA (omeprazole 20mg+furazolidone 100mg+ amoxicillin 1000mg) and OMC (omeprazole 20mg+metronidazole 200mg+clarithromycin 250mg), respectively.Each drug was taken twice daily for one week. The ^13C urea breath test was carried out 4-8 weeks after treatment to determine the success of Hpylori eradication.RESULTS:A total of 127 patients completed the treatment.The eradication rate for Hpylori infection was 90.3%,90.9%, 70.9% and 65.6%, respectively in OAC, OFC ONC and OFA groups.CONCLUSION: A high eradication rate can be achieved with one-week OAC or OFC triple therapy. Thus, one-week triple therapies with OAC and OFC are recommended for Chinese patients with duodenal ulcers and chronic gastritis.展开更多
目的:探讨影响胃肠道溃疡出血患者住院期间死亡的相关因素.方法:回顾性分析北京积水潭医院2008-06/2014-06收治的785例胃肠道溃疡出血患者的临床资料,应用单因素及Logistic多因素分析影响胃肠道溃疡出血患者死亡的危险因素.结果:785例...目的:探讨影响胃肠道溃疡出血患者住院期间死亡的相关因素.方法:回顾性分析北京积水潭医院2008-06/2014-06收治的785例胃肠道溃疡出血患者的临床资料,应用单因素及Logistic多因素分析影响胃肠道溃疡出血患者死亡的危险因素.结果:785例胃肠道溃疡出血患者住院期间死亡率为4.84%(38/785).死亡组年龄>60岁、再出血、有合并症、凝血功能异常、内镜下钛夹止血、手术止血、胃镜下喷药止血、F o r r e s t分级≤Ⅰb级、非类固醇类抗炎药(nonsteroidal anti-inflammatory drugs,NSAID)服用史、休克、幽门螺旋杆菌(Helicobacter pylori,H.pylori)阳性、嗜酒史所占比例高于治愈组(P<0.05).死亡组血清蛋白水平、血栓素A2(thromboxane A2,T X A2)水平、环氧合酶2(cyclooxygenase-2,COX-2)及H.pylori阳性率高于治愈组(P<0.05),而前列素E2(prostaglandin E2,PGE2)水平水平低于治愈组(P<0.05).经Logistic多因素分析显示,再出血(OR=4.223,95%CI:1.269-6.425)、NSAID服用史(OR=4.112,95%CI:1.326-6.986)、Forrest分级≤Ⅱb级(OR=4.692,95%C I:1.485-7.021)、TXA2(OR=4.623,95%C I:1.239-6.963)、COX-2(O R=4.265,95%C I:1.208-8.006)水平是胃肠道溃疡出血死亡的独立危险因素,而PGE2(OR=4.772,95%CI:1.277-7.236)则是保护因素.结论:再出血、NSAID服用史、Forrest分级≤Ⅰb级、TXA2、COX-2水平是胃肠道溃疡出血患者死亡的独立危险因素,而PGE2是保护因素.临床可通过相关措施促进PGE2分泌,抑制TXA2、COX-2生成,以达到治疗胃肠道溃疡出血的目的.展开更多
文摘AIM:To evaluate clinical efficacy of four one-week triple therapies in eradicating Helicobacter pylori infection.METHODS: In this clinical trial, 132 patients with duodenal ulcer and chronic gastritis were randomly divided into four groups, and received treatment with OAC (omeprazole 20mg+amoxicillin 1000mg+clarithromycin 250mg), OFC (omeprazole 20mg+furazolidone 100mg+clarithromycin 250mg), OFA (omeprazole 20mg+furazolidone 100mg+ amoxicillin 1000mg) and OMC (omeprazole 20mg+metronidazole 200mg+clarithromycin 250mg), respectively.Each drug was taken twice daily for one week. The ^13C urea breath test was carried out 4-8 weeks after treatment to determine the success of Hpylori eradication.RESULTS:A total of 127 patients completed the treatment.The eradication rate for Hpylori infection was 90.3%,90.9%, 70.9% and 65.6%, respectively in OAC, OFC ONC and OFA groups.CONCLUSION: A high eradication rate can be achieved with one-week OAC or OFC triple therapy. Thus, one-week triple therapies with OAC and OFC are recommended for Chinese patients with duodenal ulcers and chronic gastritis.
文摘目的:探讨影响胃肠道溃疡出血患者住院期间死亡的相关因素.方法:回顾性分析北京积水潭医院2008-06/2014-06收治的785例胃肠道溃疡出血患者的临床资料,应用单因素及Logistic多因素分析影响胃肠道溃疡出血患者死亡的危险因素.结果:785例胃肠道溃疡出血患者住院期间死亡率为4.84%(38/785).死亡组年龄>60岁、再出血、有合并症、凝血功能异常、内镜下钛夹止血、手术止血、胃镜下喷药止血、F o r r e s t分级≤Ⅰb级、非类固醇类抗炎药(nonsteroidal anti-inflammatory drugs,NSAID)服用史、休克、幽门螺旋杆菌(Helicobacter pylori,H.pylori)阳性、嗜酒史所占比例高于治愈组(P<0.05).死亡组血清蛋白水平、血栓素A2(thromboxane A2,T X A2)水平、环氧合酶2(cyclooxygenase-2,COX-2)及H.pylori阳性率高于治愈组(P<0.05),而前列素E2(prostaglandin E2,PGE2)水平水平低于治愈组(P<0.05).经Logistic多因素分析显示,再出血(OR=4.223,95%CI:1.269-6.425)、NSAID服用史(OR=4.112,95%CI:1.326-6.986)、Forrest分级≤Ⅱb级(OR=4.692,95%C I:1.485-7.021)、TXA2(OR=4.623,95%C I:1.239-6.963)、COX-2(O R=4.265,95%C I:1.208-8.006)水平是胃肠道溃疡出血死亡的独立危险因素,而PGE2(OR=4.772,95%CI:1.277-7.236)则是保护因素.结论:再出血、NSAID服用史、Forrest分级≤Ⅰb级、TXA2、COX-2水平是胃肠道溃疡出血患者死亡的独立危险因素,而PGE2是保护因素.临床可通过相关措施促进PGE2分泌,抑制TXA2、COX-2生成,以达到治疗胃肠道溃疡出血的目的.
